Other studies have shown that anti-CL antibody, like the lupus anticoagulant, may bind phospholipids other than cardiolipin,2 15 16 and both groups of antibodies should together be termed antiphospholipid (anti-PL) antibodies. Since phospholipids such as phosphatidylcholine and phosphatidylserine are much more widely distributed in the body than cardiolipin, the determination of differences in the binding of these antibodies to various phospholipids may be important in understanding their role in the disorders with which they are associated. Furthermore, no study has yet addressed itself to determining the distribution of anti-CL antibody isotypes in patients with these clinical disorders.
To study some of these questions we have investigated the distribution of anti-CL antibody Accepted 
INHIBITION STUDIES
To demonstrate that the assay for each phospholipid was specific a series of inhibition studies was performed. A serum positive for anti-CL antibody was preincubated with varying concentrations of phospholipid liposomes, and the inhibition of binding activity to plates coated with the phospholipids determined (Fig. 2) .
SENSITIVITY OF THE ASSAY
Serial dilutions of affinity purified IgG, IgM, and IgA anti-CL antibodies were tested for cardiolipin binding activity (Fig. 3) . The assay was able to detect IgG anti-CL antibodies down to a concentration of 20 ng/ml, IgM anti-CL antibodies to a concentration of 30 ng/ml, and IgA anti-CL antibodies to a concentration of 40 nglml.
PHOSPHOLIPID SPECIFICITY All 60 patient sera and 40 control sera were tested for binding to three phospholipids other than cardiolipin-namely, phosphatidylserine, phosphatidylinositol, and phosphatidylcholine. There were strong correlations between binding to cardiolipin, phosphatidylserine, and phosphatidylinositol (Fig.  4) , all three being negatively charged phospholipids. There was no binding to the zwitterionic phospholipid, phosphatidylcholine. 
